Host metabolites stimulate the bacterial proton motive force to enhance the activity of aminoglycoside antibiotics.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
04 2019
Historique:
received: 16 10 2018
accepted: 11 03 2019
revised: 09 05 2019
pubmed: 30 4 2019
medline: 19 10 2019
entrez: 30 4 2019
Statut: epublish

Résumé

Antibiotic susceptibility of bacterial pathogens is typically evaluated using in vitro assays that do not consider the complex host microenvironment. This may help explaining a significant discrepancy between antibiotic efficacy in vitro and in vivo, with some antibiotics being effective in vitro but not in vivo or vice versa. Nevertheless, it is well-known that antibiotic susceptibility of bacteria is driven by environmental factors. Lung epithelial cells enhance the activity of aminoglycoside antibiotics against the opportunistic pathogen Pseudomonas aeruginosa, yet the mechanism behind is unknown. The present study addresses this gap and provides mechanistic understanding on how lung epithelial cells stimulate aminoglycoside activity. To investigate the influence of the local host microenvironment on antibiotic activity, an in vivo-like three-dimensional (3-D) lung epithelial cell model was used. We report that conditioned medium of 3-D lung cells, containing secreted but not cellular components, potentiated the bactericidal activity of aminoglycosides against P. aeruginosa, including resistant clinical isolates, and several other pathogens. In contrast, conditioned medium obtained from the same cell type, but grown as conventional (2-D) monolayers did not influence antibiotic efficacy. We found that 3-D lung cells secreted endogenous metabolites (including succinate and glutamate) that enhanced aminoglycoside activity, and provide evidence that bacterial pyruvate metabolism is linked to the observed potentiation of antimicrobial activity. Biochemical and phenotypic assays indicated that 3-D cell conditioned medium stimulated the proton motive force (PMF), resulting in increased bacterial intracellular pH. The latter stimulated antibiotic uptake, as determined using fluorescently labelled tobramycin in combination with flow cytometry analysis. Our findings reveal a cross-talk between host and bacterial metabolic pathways, that influence downstream activity of antibiotics. Understanding the underlying basis of the discrepancy between the activity of antibiotics in vitro and in vivo may lead to improved diagnostic approaches and pave the way towards novel means to stimulate antibiotic activity.

Identifiants

pubmed: 31034512
doi: 10.1371/journal.ppat.1007697
pii: PPATHOGENS-D-18-02021
pmc: PMC6508747
doi:

Substances chimiques

Anti-Bacterial Agents 0
Culture Media, Conditioned 0
Tobramycin VZ8RRZ51VK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007697

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Microbiology. 2015 Oct;161(10):1961-1977
pubmed: 26253522
Infect Immun. 2008 Apr;76(4):1423-33
pubmed: 18212077
NPJ Microgravity. 2017 Feb 28;3:10
pubmed: 28649632
Sci Rep. 2017 Nov 10;7(1):15285
pubmed: 29127321
PLoS One. 2017 Nov 9;12(11):e0187540
pubmed: 29121069
Nat Rev Microbiol. 2010 Nov;8(11):791-801
pubmed: 20948552
Cell Chem Biol. 2017 Feb 16;24(2):195-206
pubmed: 28111098
Antimicrob Agents Chemother. 2000 Sep;44(9):2242-6
pubmed: 10952562
J Membr Biol. 1984;82(2):179-90
pubmed: 6096547
Appl Environ Microbiol. 2007 May;73(10):3283-90
pubmed: 17384309
J Bacteriol. 2007 Oct;189(19):6870-81
pubmed: 17644596
J Bacteriol. 2007 Nov;189(21):7600-9
pubmed: 17720796
FEMS Microbiol Rev. 2017 May 1;41(3):374-391
pubmed: 28333270
Infect Immun. 2018 Oct 25;86(11):
pubmed: 30181350
Pulm Pharmacol Ther. 2008 Aug;21(4):595-9
pubmed: 18234534
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):713-20
pubmed: 2850910
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1578-E1587
pubmed: 29382755
Front Cell Infect Microbiol. 2017 Mar 14;7:83
pubmed: 28352614
J Biol Chem. 2012 Jan 20;287(4):2887-95
pubmed: 22144679
Pathog Dis. 2014 Jun;71(1):1-19
pubmed: 24737619
Physiology (Bethesda). 2017 Jul;32(4):266-277
pubmed: 28615311
Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L25-37
pubmed: 18359885
Infect Immun. 2005 Feb;73(2):1129-40
pubmed: 15664956
PLoS One. 2018 Jan 2;13(1):e0190533
pubmed: 29293658
Curr Opin Microbiol. 2017 Oct;39:73-80
pubmed: 29049930
Antimicrob Agents Chemother. 2012 Nov;56(11):5591-602
pubmed: 22908149
Antimicrob Agents Chemother. 2003 Jan;47(1):27-33
pubmed: 12499164
Proc Natl Acad Sci U S A. 1986 Aug;83(16):6164-8
pubmed: 2426712
Microbiol Rev. 1987 Dec;51(4):439-57
pubmed: 3325794
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8856-61
pubmed: 10922046
Nature. 2011 May 12;473(7346):216-20
pubmed: 21562562
J Cyst Fibros. 2012 Jul;11(4):288-92
pubmed: 22436723
EBioMedicine. 2017 Jun;20:173-181
pubmed: 28579300
Parasitology. 1988;96 Suppl:S25-44
pubmed: 3287290
Cell Host Microbe. 2017 Dec 13;22(6):757-765.e3
pubmed: 29199098
Antimicrob Agents Chemother. 2015 Mar;59(3):1718-27
pubmed: 25583718
Sci Rep. 2017 Mar 03;7:43321
pubmed: 28256611
Cell Microbiol. 2011 Mar;13(3):469-81
pubmed: 21054742
Exp Cell Res. 2013 Jan 1;319(1):75-87
pubmed: 23022396
J Proteome Res. 2015 Mar 6;14(3):1612-20
pubmed: 25675328
Tissue Cell. 2018 Feb;50:15-30
pubmed: 29429514
Cell Metab. 2015 Feb 3;21(2):249-262
pubmed: 25651179
ACS Infect Dis. 2018 Mar 9;4(3):382-390
pubmed: 29264917
Antimicrob Agents Chemother. 2011 Jun;55(6):2655-61
pubmed: 21422204
J Biol Chem. 2010 Oct 1;285(40):30516-22
pubmed: 20675369
Pathog Dis. 2013 Nov;69(2):142-8
pubmed: 24115610
J Infect Dis. 2014 Nov 1;210(9):1357-66
pubmed: 24837402
Front Cell Infect Microbiol. 2013 Jul 09;3:24
pubmed: 23847769

Auteurs

Aurélie Crabbé (A)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Lisa Ostyn (L)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Sorien Staelens (S)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Charlotte Rigauts (C)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Martijn Risseeuw (M)

Laboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium.

Maarten Dhaenens (M)

ProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.

Simon Daled (S)

ProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.

Heleen Van Acker (H)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Dieter Deforce (D)

ProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.

Serge Van Calenbergh (S)

Laboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium.

Tom Coenye (T)

Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH